Neurology News

Positive data from a phase 1 clinical trial for bemdaneprocel, a stem cell-derived investigational therapeutic for treating Parkinson’s disease, have been announced by its manufacturer.

Possible biomarkers of an adolescent’s risk for developing mental health issues include alterations in proteins involved with immune responses, blood coagulation and other pathways, data show.

A Bay Area-based biopharmaceutical company has announced initiation of a phase 1 clinical trial for its oral, small molecule SARM1 inhibitor, NB-4746, to treat a wide range of conditions affecting the central, peripheral and ocular nervous systems.

Although generally safe and well-tolerated, venglustat treatment for adults with GBA-1 associated Parkinson’s disease was not superior to placebo after 1 year, per data from the Lancet Neurology.

Switching older patients with frailty syndrome and atrial fibrillation to a non-vitamin K antagonist from their old blood thinner caused significant bleeding risk and no greater protection from stroke, a speaker reported.

The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with relapsing forms of multiple sclerosis.

A clinical-stage biotechnology company announced that it has raised $150 million in funding to advance its neuromedicine platform.

Individuals with Parkinson’s disease present with reduced thickness of two key components of the retina, which may indicate retinal optical coherence tomography as a vital tool in early disease detection, data show.

Subcallosal cingulate gyrus deep brain stimulation was generally safe and significantly improved depressive symptoms in patients with treatment-resistant depression, with results sustained up to 7 years, according to research.

Among individuals aged 18 years or younger, neighborhood-level deprivation did not raise the odds for severe obstructive sleep apnea, according to results published in Laryngoscope Investigative Otolaryngology.